Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Osimertinib and dacomitinib are approved as first-line treatment of EGFR-mutant NSCLC but resistance can arise. Here, the authors use a computational model to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy that was confirmed tolerable and effective in an ongo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kamrine E. Poels, Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O. McDonald, Weiwei Tan, Aaron Hata, Scott L. Weinrich, Helena A. Yu, Franziska Michor
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/f560d9720b2540fab5539f7d8afa3e27
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares